Long-Acting Injectable Cabotegravir for HIV Prevention is Safe in Pregnancy
Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in a global study among cisgender women, with findings to be presented at the 2024 International AIDS Conference.
Related Clinical Trials
Highlighted Terms
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institutes of HealthHIV Prevention Trials NetworkUniversity of the WitwatersrandNCT03164564Gilead Sciences, Inc.Bill & Melinda Gates FoundationNational Institute of Allergy and Infectious DiseasesNational Institute on Drug AbuseViiV HealthcareHIVNational Institute of Mental HealthCabotegravir
Related News
Long-Acting Injectable Cabotegravir for HIV Prevention is Safe in Pregnancy
Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in a global study among cisgender women, with findings to be presented at the 2024 International AIDS Conference.